Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1999 2
2000 1
2002 2
2005 3
2006 2
2008 2
2009 1
2010 3
2011 3
2012 1
2013 1
2014 1
2017 2
2018 4
2019 1
2020 3
2021 5
2022 10
2023 10
2024 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study.
Menzies-Gow A, Wechsler ME, Brightling CE, Korn S, Corren J, Israel E, Chupp G, Bednarczyk A, Ponnarambil S, Caveney S, Almqvist G, Gołąbek M, Simonsson L, Lawson K, Bowen K, Colice G; DESTINATION study investigators. Menzies-Gow A, et al. Lancet Respir Med. 2023 May;11(5):425-438. doi: 10.1016/S2213-2600(22)00492-1. Epub 2023 Jan 23. Lancet Respir Med. 2023. PMID: 36702146 Clinical Trial.
Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma.
Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S, Goldman M; ZONDA Trial Investigators. Nair P, et al. N Engl J Med. 2017 Jun 22;376(25):2448-2458. doi: 10.1056/NEJMoa1703501. Epub 2017 May 22. N Engl J Med. 2017. PMID: 28530840 Free article. Clinical Trial.
Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study.
Wechsler ME, Menzies-Gow A, Brightling CE, Kuna P, Korn S, Welte T, Griffiths JM, Sałapa K, Hellqvist Å, Almqvist G, Lal H, Kaur P, Skärby T, Colice G; SOURCE study group. Wechsler ME, et al. Lancet Respir Med. 2022 Jul;10(7):650-660. doi: 10.1016/S2213-2600(21)00537-3. Epub 2022 Mar 29. Lancet Respir Med. 2022. PMID: 35364018 Clinical Trial.
Further considerations regarding myocarditis.
Ediger DS, Brady WJ, Koyfman A, Long B. Ediger DS, et al. Am J Emerg Med. 2024 May;79:221-222. doi: 10.1016/j.ajem.2024.02.002. Epub 2024 Feb 4. Am J Emerg Med. 2024. PMID: 38365530 No abstract available.
Picturing asthma in Turkey: results from the Turkish adult asthma registry.
Celik GE, Aydin O, Gokmen D, Koycu Buhari G, Celebi Sozener Z, Gemicioglu B, Bulut I, Beyaz S, Orcen C, Ozdemir SK, Keren M, Damadoglu E, Yakut T, Kalpaklioglu AF, Baccioglu A, Yalim SA, Yilmaz I, Koca Kalkan I, Uysal MA, Ozgun Niksarlioglu EY, Kalyoncu AF, Karakaya G, Erbay M, Nayci S, Tepetam FM, Gelincik AA, Dirol H, Goksel O, Karaoglanoglu S, Oner Erkekol F, Isik SR, Yildiz F, Yavuz Y, Karadogan D, Bozkurt N, Seker U, Oguzulgen IK, Basyigit I, Baris SA, Yilmazel Ucar E, Erdogan T, Polatli M, Ediger D, Gunaydin FE, Turk M, Pur L, Katran ZY, Sekibag Y, Aykac EF, Mungan D, Gul O, Cengiz A, Akkurt B, Ozden S, Demir S, Unal D, Aslan AF, Can A, Gumusburun R, Bogatekin G, Akten HS, Inan S, Erdinc M, Ogus AC, Kavas M, Polat Yulug D, Cakmak ME, Kaya SB, Alpagat G, Ozgur ES, Uzun O, Tas Gulen S, Pekbak G, Kizilirmak D, Havlucu Y, Donmez H, Arslan B, Cetin GP, Soyyigit S, Kara BY, Pasaoglu Karakis G, Dursun AB, Kendirlinan R, Ozturk AB, Sevinc C, Omeroglu Simsek G, Abadoglu O, Cerci P, Yucel T, Yorulmaz I, Tezcaner ZC, Tatar EC, Suslu AE, Ozer S, Dursun E, Yorgancioglu A. Celik GE, et al. Among authors: ediger d. J Asthma. 2023 Nov;60(11):1973-1986. doi: 10.1080/02770903.2023.2206902. Epub 2023 May 31. J Asthma. 2023. PMID: 37096963
Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs in adults: Beyond current classification.
Çerçi P, Kendirlinan R, Büyüköztürk S, Gelincik A, Ünal D, Demir S, Erkekol FÖ, Karakaya G, Dursun AB, Çelikel S, Ediger D, Abadoglu O, Bavbek S. Çerçi P, et al. Among authors: ediger d. Allergol Immunopathol (Madr). 2023 Sep 1;51(5):84-92. doi: 10.15586/aei.v51i5.946. eCollection 2023. Allergol Immunopathol (Madr). 2023. PMID: 37695234
High risk and low prevalence diseases: Myocarditis.
Ediger DS, Brady WJ, Koyfman A, Long B. Ediger DS, et al. Am J Emerg Med. 2024 Apr;78:81-88. doi: 10.1016/j.ajem.2024.01.007. Epub 2024 Jan 9. Am J Emerg Med. 2024. PMID: 38241774 Review.
Prognostic factors for COVID-19 patients.
Önal U, Aydın Güçlü Ö, Akalın H, Aylin Acet Öztürk N, Semet C, Demirdöğen E, Görek Dilektaşlı A, Sağlık İ, Kazak E, Özkaya G, Coşkun F, Ediger D, Heper Y, Ursavaş A, Yılmaz E, Uzaslan E, Karadağ M. Önal U, et al. Among authors: ediger d. J Infect Dev Ctries. 2022 Mar 31;16(3):409-417. doi: 10.3855/jidc.15845. J Infect Dev Ctries. 2022. PMID: 35404844 Free article.
Fatigue: A forgotten symptom of asthma.
Günaydın FE, Ediger D, Erbay M. Günaydın FE, et al. Among authors: ediger d. Clin Respir J. 2021 Jul;15(7):741-752. doi: 10.1111/crj.13356. Epub 2021 Mar 29. Clin Respir J. 2021. PMID: 33783133
57 results